Latest Press Releases

• Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US

  May 2, 2012

  Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction.

  read more English PDF

• Nordic Capital-led group sells Fougera

  May 2, 2012

  A consortium of private equity funds led by Nordic Capital Funds V and VI ("Nordic Capital"), including DLJ Merchant Banking Partners (a Credit Suisse affiliate) and Avista Capital Partners, today announced a definitive agreement to sell Fougera Pharmaceuticals Inc. ("Fougera" or "the Company") to Sandoz, the generics division of Novartis, at a transaction value of USD 1,525 million on a debt and cash free basis.

  read more English PDF